



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **Surgical Management of Early Hepatocellular Carcinoma**

Thesis

Submitted for Partial Fulfilment of Master Degree  
in General Surgery

By

**Alshimaa Khalil Abdelmonem Marie**

M.B,B.Ch

Faculty of Medicine, Cairo university

Under supervision of

**Prof. Dr. Adel Abdel Aziz Ewada**

*Professor of General Surgery*

*Faculty of medicine, Ain Shams University*

**Dr. Sherif Boraii Mohamed**

*Lecturer of General Surgery*

*National hepatology and Tropical Medicine Research Institute*

*Faculty of Medicine*

*Ain Shams University*

*2020*



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سَبِّحْ اِنَّكَ لَا تَعْلَمُ لَنَا  
اِلَّا مَا عَلَّمْتَنَا اِنَّكَ اَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Adel Abdel Aziz Ewada**, Professor of General Surgery, Faculty of medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Sherif Boraii Mohamed**, Lecturer of General Surgery, National Hepatology and Tropical Medicine Research Institute, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

**Alshimaa Khalil**

# List of Contents

Title	Page No.
List of Tables .....	i
List of Figures .....	iv
List of Abbreviations.....	vii
Introduction .....	1
Aim of the Work.....	4
Review of Literature	
Clinical and Surgical Anatomy of the Liver .....	5
Hepatocellular Carcinoma (Epidemiology, Pathogenesis and Diagnosis).....	16
Staging of HCC .....	27
Treatment of Early HCC .....	47
Patients and Methods.....	65
Results .....	72
Discussion .....	105
Summary and Conclusion.....	114
Limitations.....	117
Recommendations .....	118
References .....	119
Arabic Summary .....	—

# List of Tables

Table No.	Title	Page No.
Table (1):	Hepatic Cell Types and Their Specific Function .....	7
Table (2):	Proper Hepatic Resections and the Included Segments.....	10
Table (3):	Comparison of different hepatocellular carcinoma staging systems: tumor and patient characteristics and liver function .....	30
Table (4):	Okuda staging and its elements .....	40
Table (5):	The Cancer of the Liver Italian Program score and its elements.....	42
Table (6):	The elements of the ITA.LI.CA tumor staging system and the integrated prognostic score .....	46
Table (7):	Specificities of hepatocellular carcinoma (HCC) in cirrhosis with respect to cirrhosis lacking HCC at the time of transplant consideration.....	49
Table (8):	Allocation models considered for liver transplantation.....	50
Table (9):	Selection criteria in liver transplantation for HCC* .....	51
Table (10):	Socio-demographic data among 50 early HCC patients: .....	72
Table (11):	Basic clinical data among 50 early HCC patients: .....	73
Table (12):	Laboratory data among 50 early HCC patients: .....	75
Table (13):	Radiological data among 50 early HCC patients: .....	76



# List of Tables Cont...

Table No.	Title	Page No.
Table (14):	Intra-operative data among 50 early HCC patients: .....	81
Table (15):	Post-operative complications among 50 early HCC patients:.....	84
Table (16):	Post-operative follow-up data among 50 early HCC patients:.....	85
Table (17):	Comparison between the 2 groups as regards socio-demographic data using Mann-Whitney's U and Chi square tests: .....	86
Table (18):	Comparison between the 2 groups as regards basic clinical data using Chi square test:.....	87
Table (19):	Comparison between the 2 groups as regards laboratory data using Mann-Whitney's U test:.....	89
Table (20):	Comparison between the 2 groups as regards radiological data using Mann-Whitney's U and Chi square tests:.....	90
Table (21):	Comparison between the 2 groups as regards intra-operative data using Mann-Whitney's U and Chi square tests:.....	92
Table (22):	Comparison between the 2 groups as regards post-operative complications using Chi square test: .....	95
Table (23):	Comparison between the 2 groups as regards post-operative follow-up data using Mann-Whitney's U test:.....	97
Table (24):	Multiple regression model for the Factors affecting ICU stay using Forward method:.....	100

## List of Tables Cont...

Table No.	Title	Page No.
<b>Table (25):</b>	Multiple regression model for the Factors affecting hospital stay using Forward method:.....	101
<b>Table (26):</b>	Multiple regression model for the Factors affecting drain removal days using Forward method:.....	102
<b>Table (27):</b>	Logistic regression model for the Factors affecting complications occurrence using Forward method:.....	103
<b>Table (28):</b>	Roc-curve of laparoscopic resection to predict efficacy (decreased hospital stay):.....	104

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Posterior view of hepatic anatomy .....	6
<b>Figure (2):</b>	Hepatic lobule demonstrating the portal triad draining toward a central vein via hepatocyte-lined sinusoidal capillary .....	8
<b>Figure (3):</b>	CT imaging through the liver.....	13
<b>Figure (4):</b>	Couinaud liver segments.....	14
<b>Figure (5):</b>	(A) Hepatic veins, (R) Right, (M) Middle, and (L) Left, creating four hepatic divisions. Right and left hemilivers separated by Cantlie's line. (B) Veins overlaid on our hand model of the liver .....	15
<b>Figure (6):</b>	Pathogenesis of HCC and targets for chemopreventive agents .....	23
<b>Figure (7):</b>	TACE.....	25
<b>Figure (8):</b>	Typical HCC shows arterial phase hypervascularity with washout of contrast on portal venous and equilibrium phase .....	26
<b>Figure (9):</b>	Timeline for development of various clinical HCC staging systems.....	29
<b>Figure (10):</b>	The Barcelona Clinic Liver Cancer classification.....	31
<b>Figure (11):</b>	The Alberta HCC algorithm .....	36
<b>Figure (12):</b>	The HKLC classification.....	38
<b>Figure (13):</b>	CT of a large heterogeneous hepatocellular carcinoma treated with sorafenib .....	58
<b>Figure (14):</b>	Survival data starting follow-up at different time points .....	63

# List of Figures Cont...

Fig. No.	Title	Page No.
Figure (15):	BCLC (Barcelona clinic liver cancer) staging system for early HCC .....	66
Figure (16):	Gender among 50 early HCC patients. ....	73
Figure (17):	Basic clinical data among 50 early HCC patients.....	74
Figure (18):	Radiological data among 50 early HCC patients.....	78
Figure (19):	Segments affected in MRI & Triphasic CT. ....	78
Figure (20):	HCC: MRI with liver-specific contrast agent (gadoteric acid).....	79
Figure (21):	HCC: quadruple-phasic CT for detection and characterization.....	80
Figure (22):	Laparoscopic resection. ....	82
Figure (23):	Open resection. ....	82
Figure (24):	Resection type among 50 early HCC patients.....	83
Figure (25):	Type of operation among 50 early HCC patients.....	83
Figure (26):	Post-operative complications among 50 early HCC patients.....	84
Figure (27):	Comparison between the 2 groups as regards Child-Pugh class.....	88
Figure (28):	Comparison between the 2 groups as regards size of lesion. ....	91
Figure (29):	Comparison between the 2 groups as regards operative time. ....	93
Figure (30):	Comparison between the 2 groups as regards blood loss. ....	93

# List of Figures Cont...

Fig. No.	Title	Page No.
Figure (31):	Comparison between the 2 groups as regards blood transfusion units.....	94
Figure (32):	Comparison between the 2 groups as regards plasma transfusion units. ....	94
Figure (33):	Comparison between the 2 groups as regards ascites. ....	96
Figure (34):	Comparison between the 2 groups as regards ICU stay. ....	97
Figure (35):	Comparison between the 2 groups as regards hospital stay. ....	98
Figure (36):	Comparison between the 2 groups as regards drain removal days .....	98
Figure (37):	Correlation between ICU stay and operative time. ....	100
Figure (38):	Correlation between hospital stay and operative time. ....	101
Figure (39):	Correlation between drain removal days and age.....	102
Figure (40):	Correlation between drain removal days and operative time. ....	103
Figure (41):	ROC curve of laparoscopic resection.....	104

# List of Abbreviations

Abb.	Full term
3D .....	Three-dimensional
AASLD.....	American Association for the Study of Liver Diseases
AFP.....	Alpha fetoprotein
AJCC .....	American Joint Committee on Cancer
Alb .....	Albumin
ALP.....	Alkaline phosphatase
ALT.....	Alanine transaminase
ALTSG .....	American Liver Tumor Study Group-modified Tumor-Node-Metastasis classification
AST.....	Aspartate transaminase
AUC .....	Area under curve
BCLC .....	Barcelona clinic liver cancer
CLIP .....	Cancer of the Liver Italian Program
Creat.....	Creatinine
CT.....	Computed tomography
CTP.....	Child-Turcotte-Pugh
CUPI.....	Chinese University Prognostic Index
EASL .....	European Association for the Study of the Liver
ECOG PS.....	Eastern Cooperative Oncology Group performance status
ECOG .....	Eastern Cooperative Oncology Group
GRETCH.....	Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire
Hb .....	Hemoglobin
HBV .....	Hepatitis B virus
HCC .....	Hepatocellular carcinoma
HCV.....	Hepatitis C virus
HVPG .....	Hepatic venous pressure gradient

# List of Abbreviations Cont...

Abb.	Full term
IHPBA.....	International Hepato-Pancreato-Biliary Association
INR .....	International normalized ratio
ITT .....	Intention-to-treat
JIS .....	Japanese Integrated Staging
LCSGJ.....	Liver Cancer Study Group of Japan
LR .....	Liver resection
LT .....	Liver transplantation
MAPK.....	Ras-mitogen-activated protein kinase
MC .....	Milan Criteria
MELD .....	Model of end-stage liver disease
MRI.....	Magnetic resonance imaging
mTOR.....	Mammalian target of rapamycin
NAFLD .....	Nonalcoholic fatty liver disease
NASH .....	Nonalcoholic steatohepatitis
NCCN .....	National Comprehensive Cancer Network
NHTMRI .....	National hepatology and tropical medicine research institute
PFS .....	Progression-free survival
PI3K.....	Phosphatidylinositol 3-kinase
PLT .....	Platelets
PS .....	Performance scale
PVT.....	Portal vein thrombosis
RCTs.....	Randomized controlled trials
RFA.....	Radiofrequency ablation
ROC .....	Receiver operating characteristic
SE .....	Standard Error
SEER .....	Surveillance Epidemiology End Result
T Bil.....	Total bilirubin